Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunotoxin in Treating Patients With Leukemia or Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00002765
Recruitment Status : Completed
First Posted : May 6, 2003
Last Update Posted : April 29, 2015
Sponsor:
Information provided by:
National Cancer Institute (NCI)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of LMB-2 immunotoxin in treating patients who have leukemia or lymphoma.


Condition or disease Intervention/treatment Phase
Leukemia Lymphoma Biological: LMB-2 immunotoxin Phase 1

Detailed Description:

OBJECTIVES:

  • Assess the therapeutic efficacy and toxicity of the recombinant immunotoxin LMB-2, an anti-Tac murine monoclonal antibody fragment conjugated to a truncated portion of Pseudomonas exotoxin, in patients with Tac-expressing leukemias and lymphomas.
  • Define the pharmacokinetics of LMB-2, including the terminal elimination serum half-life, area under the curve, and volume of distribution.
  • Evaluate, in a preliminary manner, the immunogenicity of LMB-2 in these patients.
  • Determine the effect of LMB-2 on various components of the circulating cellular immune system.

OUTLINE: This is a dose escalation study.

Patients receive LMB-2 immunotoxin IV over 30 minutes on days 1, 3, and 5. Treatment repeats every 15-21 days for up to 10 courses in the absence of disease progression, neutralizing antibodies, or unacceptable toxicity.

Cohorts of 3-6 patients each receive escalating doses of LMB-2 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 patient experiences dose limiting toxicity.

PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for this study.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: PHASE I STUDY OF ANTI-TAC(Fv)-PE38 (LMB-2), A RECOMBINANT SINGLE-CHAIN IMMUNOTOXIN FOR TREATMENT OF TAC-EXPRESSING MALIGNANCIES
Study Start Date : April 1996

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia Lymphoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed Hodgkin's disease, non-Hodgkin's lymphoma, or leukemia in one of the following categories:

    • Adult T-cell leukemia or lymphoma (ATL)

      • No smoldering ATL
      • No limitation on prior therapy

    • Cutaneous T-cell lymphoma (CTCL)

      • Stages IB-III and failed at least 1 standard therapy
      • Stage IV regardless of prior therapy

    • Stages I-IV peripheral T-cell lymphoma

      • Relapsed after standard chemotherapy
      • Ineligible for or refused salvage chemotherapy or bone marrow transplantation (BMT)

    • B-cell non-Hodgkin's lymphoma (NHL) of any histology

      • Indolent stages II-IV NHL

        • Failed at least 1 standard therapy
        • Disease symptomatic and requiring treatment

      • Aggressive NHL

        • Relapsed after standard chemotherapy
        • Ineligible for or refused salvage chemotherapy or BMT

    • Chronic lymphocytic leukemia (CLL)

      • Rai stages III and IV or Binet stage C
      • Failed standard therapy and at least 1 salvage chemotherapy

    • Primary B-cell prolymphocytic leukemia or prolymphocytic transformation of CLL

      • Failed standard therapy and at least 1 salvage chemotherapy

    • Hairy cell leukemia

      • Failed standard and salvage chemotherapy
      • Ineligible for or refused further salvage chemotherapy or BMT

    • Acute myelogenous leukemia

      • Failed standard chemotherapy
      • Ineligible for or refused salvage chemotherapy or BMT

    • Stages II-IV Hodgkin's disease

      • Failed standard chemotherapy
      • Ineligible for curative salvage radiotherapy or chemotherapy
      • Ineligible for or refused BMT
    • Patients with leukemias or lymphomas not easily classified in above categories who have failed standard therapy and are ineligible for or have refused bone marrow transplant

  • Evidence of interleukin-2 receptor-alpha (IL2Ra) expression by one of the following:

    • Greater than 10% of malignant cells reactive with anti-Tac by immunohistochemistry
    • Greater than 10% of malignant cells from a particular site positive by FACS
    • Greater than 400 IL2Ra sites per malignant cell by radiolabeled anti-Tac binding
    • Soluble IL2Ra level greater than 1,000 U/mL (normal geometric mean 235, with 95% confidence levels of 112-502 U)
    • Hodgkin's disease with measurable disease not amenable to biopsy

  • No CNS disease requiring treatment

    • Malignant cells in CSF allowed if judged not to represent clinically significant leukemic or lymphomatous meningitis (as in CSF contamination by blood)

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 50-100%

Life expectancy:

  • Greater than 2 months

Hematopoietic:

  • Absolute neutrophil count greater than 1,000/mm3*
  • Platelet count greater than 50,000/mm3* NOTE: *nonleukemic patients

Hepatic:

  • AST and ALT less than 5 times normal

Renal:

  • Creatinine less than 2.0 mg/dL OR
  • Creatinine clearance greater than 50 mL/min

Pulmonary:

  • FEV1, TLC, and DLCO greater than 50% of predicted if pulmonary or mediastinal involvement with tumor greater than one third of total thoracic diameter

Other:

  • HIV negative
  • Not pregnant
  • Fertile patients must use effective contraception
  • Serum must neutralize no more than 75% LMB-2 in tissue culture

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics
  • At least 3 weeks since prior interferon

Chemotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior cytotoxic chemotherapy
  • At least 3 weeks since prior retinoids
  • No concurrent chemotherapy

Endocrine therapy:

  • No concurrent corticosteroids unless begun at least 3 weeks prior to entry and dose not increased during 3 weeks prior to entry

Radiotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior whole-body electron beam radiotherapy
  • Other radiotherapy allowed within 3 weeks of entry provided less than 10% of marrow irradiated and measurable disease exists outside radiation port

Surgery:

  • Not specified

Other:

  • See Disease Characteristics
  • At least 3 weeks since any prior systemic therapy
  • No other concurrent investigational agents
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002765


Locations
Layout table for location information
United States, Maryland
Laboratory of Molecular Biology
Bethesda, Maryland, United States, 20892
Medicine Branch
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Study Chair: Robert Kreitman, MD National Cancer Institute (NCI)
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Other Publications:

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00002765    
Obsolete Identifiers: NCT00001501
Other Study ID Numbers: CDR0000064729
NCI-96-C-0064F
NCI-T95-0042N
First Posted: May 6, 2003    Key Record Dates
Last Update Posted: April 29, 2015
Last Verified: March 2003
Keywords provided by National Cancer Institute (NCI):
recurrent adult Hodgkin lymphoma
stage IV cutaneous T-cell non-Hodgkin lymphoma
recurrent cutaneous T-cell non-Hodgkin lymphoma
Waldenström macroglobulinemia
recurrent adult acute myeloid leukemia
recurrent adult acute lymphoblastic leukemia
relapsing chronic myelogenous leukemia
refractory chronic lymphocytic leukemia
refractory hairy cell leukemia
recurrent small lymphocytic lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma
 recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent adult Burkitt lymphoma
stage I adult T-cell leukemia/lymphoma
stage II adult T-cell leukemia/lymphoma
stage III adult T-cell leukemia/lymphoma
stage IV adult T-cell leukemia/lymphoma
recurrent adult T-cell leukemia/lymphoma
prolymphocytic leukemia
recurrent mantle cell lymphoma
stage IV mycosis fungoides/Sezary syndrome
recurrent mycosis fungoides/Sezary syndrome
recurrent marginal zone lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
 Immunoproliferative Disorders
Immune System Diseases
Immunotoxins
Immunologic Factors
Physiological Effects of Drugs